Results 121 to 130 of about 35,982 (205)

Essential role of MHC II in the antitubercular efficacy of pyrazinamide. [PDF]

Antimicrob Agents Chemother
Lamont EA, Kordus SL, Howe MD, Jia Z, Schacht N, Rather MA, Gebretsadik G, Baughn AD.   +7 more
europepmc   +1 more source

Current treatment options for latent tuberculosis infection [PDF]

, 2014
BOCCHINO, MARIALUISA, Matarese, Alessandro, SANDUZZI ZAMPARELLI, ALESSANDRO   +2 more
core   +1 more source

Targeting <i>Mycobacterium tuberculosis</i>: The Role of Alkyl Substitution in Pyrazinamide Derivatives. [PDF]

ACS Omega
Juhás M, Bouz G, Pang L, Weeks SD, Jand́ourek O, Konečná K, Paterová P, Bárta P, Halířová M, Kučerová-Chlupáčová M, Doležal M, Zitko J.   +11 more
europepmc   +1 more source

A scoping review of interventions to prevent and treat adverse events during treatment of rifampin-susceptible tuberculosis. [PDF]

PLoS One
Burman WJ, Martins MF, Flynn D, Johnston J, Sinha P, Horsburgh CR.   +5 more
europepmc   +1 more source

Targeted next-generation sequencing for drug-resistant tuberculosis diagnosis: implementation considerations for bacterial load, regimen selection and diagnostic algorithm placement. [PDF]

BMJ Glob Health
Georghiou SB, Tukvadze N, Rodrigues C, Omar SV, Cabibbe AM, Seifert M, Uplekar S, Ismail N, Ruhwald M, Suresh A, Colman RE.   +10 more
europepmc   +1 more source

Rifapentine- and moxifloxacin-containing short-course regimens for mild spinal tuberculosis: study protocol for a multicenter, randomized, non-inferiority phase II clinical trial. [PDF]

Front Pharmacol
Wu YE, Cao J, Wang L, Wei YJ, Liu HX, Qi L, Zhang W, Liu F, Zhu ZJ, Fan XT, Wang S, Chen C, Liu XZ, Li Y, Sun ZZ, Pan JB, Yang CQ, Van Den Anker J, Zhang Q, Zhao W.   +19 more
europepmc   +1 more source

A Study of the Association of Cerebrospinal Fluid Neutrophil-to-Lymphocyte Ratio with Severity and Mortality in Patients with Tuberculous Meningitis. [PDF]

Ann Indian Acad Neurol
Mateen S, Siddiqi Z, Singh S, Singh A, Khan M.   +4 more
europepmc   +1 more source

Therapeutic drug monitoring-guided treatment of XDR TB with an RpoB I491F mutation-a case report. [PDF]

JAC Antimicrob Resist
Klingmüller A, Zuber S, Hoffmann AM, Köhler N, Suárez I, Preßel T, Niemann S, Dreyer V, Decosterd LA, Choong E, Schütz B, Friesen I, Rybniker J.   +12 more
europepmc   +1 more source

Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials. [PDF]

IJTLD Open
Nedelman J, Li M, Olugbosi M, Bruning-Barry R, Ambroso J, Cevik M, Gillespie S, Sloan DJ, Beumont M, Sun E.   +9 more
europepmc   +1 more source

Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis. [PDF]

Antimicrob Agents Chemother
Calderin JM, Wasserman S, Resendiz-Galvan JE, Abdelgawad N, Davis A, Stek C, Wiesner L, Wilkinson RJ, Denti P.   +8 more
europepmc   +1 more source